Latest news with #TISSIUM
Yahoo
05-06-2025
- Business
- Yahoo
TISSIUM selected for the French Tech 120 Program
Paris, France, June 5, 2025 -- TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the sixth year in a row in the French Tech 120 Program by joining the 2025 class. Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the 120 most promising French start-ups, who have the potential to become world-class technology leaders. TISSIUM will benefit from daily, personalized support throughout the 2025 class. The aim of the program is to provide individual and collective support on strategic issues such as international development, financing, recruitment, industrial implantation, intellectual property, and regulatory issues. Start-ups will thus be able to rely on a dedicated start-up manager within the Mission French Tech, enhanced visibility, specific support on regulatory issues, and collective support in the form of experience-sharing events and expertise contributions. 'We are delighted to once again be part of the French Tech 120 program, particularly in 2025 where we continue the expansion of our activities in each of our therapeutic indications and the achievement of important clinical and regulatory milestones in preparation for the upcoming commercialization of our first products. For the sixth consecutive year, this recognition is a validation of our ongoing commitment to innovate and grow in order to transform the field of tissue reconstruction.' said Christophe Bancel, CEO of TISSIUM. About Mission French Tech Mission French Tech is the government mission tasked, since 2013, with supporting the structuring and growth of the French start-up ecosystem, in France and internationally. Attached to the Direction Générale des Entreprises, within the Ministère de l'Économie, des Finances et de la Souveraineté Industrielle et Numérique, it federates and animates the French Tech ecosystem with a network of 17 Capitales and nearly a hundred labeled French Tech Communities, in France and in 52 countries around the world. It also supports start-ups by facilitating their interactions with the administration via a network of over 60 French Tech correspondents. Mission French Tech supports the most mature start-ups through the French Tech Next40/120 program and start-ups positioned in sectors identified as strategic within the framework of France 2030 with the French Tech 2030 program. Find all the information on the French Tech Next40/120 on the Mission French Tech website: Mission French Tech press contact: About TISSIUM TISSIUM is a MedTech company headquartered in Paris, France, with operations in Cambridge, USA, and a manufacturing site in the North of France (Ronq). The company is pioneering a proprietary platform of fully biosynthetic, biomorphic, and programmable polymers designed to address critical unmet needs in atraumatic tissue repair and tissue reconstruction. TISSIUM's diversified pipeline includes seven products across three core verticals: sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. Each solution is engineered to optimize tissue reconstruction through controlled and consistent application with specialized delivery and activation devices to maximize the performance and usability of its products. Founded in 2013, TISSIUM is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital). For more information, please visit and follow us on LinkedIn: TISSIUM. *** Contact Romain Attard – Chief Financial Officer rattard@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
TISSIUM selected for the French Tech 120 Program
Paris, France, June 5, 2025 -- TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, confirms its selection for the sixth year in a row in the French Tech 120 Program by joining the 2025 class. Launched in 2019 by the Mission French Tech, the French Tech 120 is a program from the Government to support the 120 most promising French start-ups, who have the potential to become world-class technology leaders. TISSIUM will benefit from daily, personalized support throughout the 2025 class. The aim of the program is to provide individual and collective support on strategic issues such as international development, financing, recruitment, industrial implantation, intellectual property, and regulatory issues. Start-ups will thus be able to rely on a dedicated start-up manager within the Mission French Tech, enhanced visibility, specific support on regulatory issues, and collective support in the form of experience-sharing events and expertise contributions. 'We are delighted to once again be part of the French Tech 120 program, particularly in 2025 where we continue the expansion of our activities in each of our therapeutic indications and the achievement of important clinical and regulatory milestones in preparation for the upcoming commercialization of our first products. For the sixth consecutive year, this recognition is a validation of our ongoing commitment to innovate and grow in order to transform the field of tissue reconstruction.' said Christophe Bancel, CEO of TISSIUM. About Mission French Tech Mission French Tech is the government mission tasked, since 2013, with supporting the structuring and growth of the French start-up ecosystem, in France and internationally. Attached to the Direction Générale des Entreprises, within the Ministère de l'Économie, des Finances et de la Souveraineté Industrielle et Numérique, it federates and animates the French Tech ecosystem with a network of 17 Capitales and nearly a hundred labeled French Tech Communities, in France and in 52 countries around the world. It also supports start-ups by facilitating their interactions with the administration via a network of over 60 French Tech correspondents. Mission French Tech supports the most mature start-ups through the French Tech Next40/120 program and start-ups positioned in sectors identified as strategic within the framework of France 2030 with the French Tech 2030 program. Find all the information on the French Tech Next40/120 on the Mission French Tech website: Mission French Tech press contact: About TISSIUM TISSIUM is a MedTech company headquartered in Paris, France, with operations in Cambridge, USA, and a manufacturing site in the North of France (Ronq). The company is pioneering a proprietary platform of fully biosynthetic, biomorphic, and programmable polymers designed to address critical unmet needs in atraumatic tissue repair and tissue reconstruction. TISSIUM's diversified pipeline includes seven products across three core verticals: sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. Each solution is engineered to optimize tissue reconstruction through controlled and consistent application with specialized delivery and activation devices to maximize the performance and usability of its products. Founded in 2013, TISSIUM is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital). For more information, please visit and follow us on LinkedIn: TISSIUM. *** Contact Romain Attard – Chief Financial Officer rattard@
Yahoo
02-04-2025
- Health
- Yahoo
TISSIUM Announces Clinical Results of COAPTIUM® CONNECT System for Atraumatic Sutureless Nerve Repair
Paris, France, Cambridge, USA, April 2nd, 2025 - TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, is proud to unveil clinical data which were presented at the IFSSH Congress in Washington, D.C. on March 27, 2025, demonstrating the potential of its COAPTIUM® CONNECT System, an innovative atraumatic sutureless solution for peripheral nerve repair. Peripheral nerve injuries pose a significant burden, often resulting in impaired nerve function, reduced dexterity, and decreased quality of life. Traditional microsurgical repair with sutures, while effective, presents challenges such as inconsistent functional recovery and the potential for additional nerve trauma. The need for disruptive technologies in nerve repair is clear—TISSIUM's COAPTIUM® CONNECT System offers an innovative atraumatic sutureless method for coaptation of severed nerves. Study Overview & Key Findings A prospective, single-arm study was conducted in patients with digital nerve injuries to assess the COAPTIUM® CONNECT System. The trial enrolled 12 patients, of whom 10 completed the entire 1-year follow-up duration. 100% procedural success was achieved, defined as successful atraumatic sutureless coaptation using the polymer-assisted coaptation device ; All patients regained full flexion and extension of the injured digit ; All patients reported no pain (VAS pain score) at 12 months ; No study device-related complications were reported for the complete 12-month follow-up ; No neuromas occurred. TISSIUM would like to thank our study investigators Professor Randy Bindra, MD at the Gold Coast University Hospital and Dr. Michael Wagels at the Princess Alexandra Hospital and their study teams for their commitment to atraumatic treatment of digital nerve injuries. The COAPTIUM® CONNECT System has been designed for atraumatic sutureless consistent nerve repair. It leverages TISSIUM's unique biopolymer platform and is comprised of a bioresorbable light-activated surgical polymer and a protective coaptation chamber. When asked about his experience in this study, Dr. Randy Bindra, Professor of Orthopedic Surgery and principal trial investigator at the Gold Coast University Hospital and Griffith University School of Medicine said 'In my 30 years of experience of repairing nerves, this is one product where the clinical trial results have surpassed my expectation. All patients were pain free and had excellent outcomes.' 'I am optimistic this new technology can bring us a step closer to better nerve repair outcomes in the future. Removing the need for sutures will allow improved regeneration of the nerve, benefiting the patient long term,' said Dr. Michael Wagels, Director of the Australian Centre for Complex Integrated Surgical Solutions, Department of Plastic and Reconstructive Surgery, Princess Alexandra Hospital. The COAPTIUM® CONNECT System represents a meaningful advancement in nerve surgery, offering an innovative atraumatic sutureless method for coaptation of severed nerves. By eliminating the need for microsutures, this technology streamlines nerve repair while preserving nerve integrity and function. TISSIUM remains committed to advancing innovation in tissue reconstruction and is actively exploring the expansion of the COAPTIUM® platform for broader applications in nerve repair. The COAPTIUM® CONNECT System is not approved or cleared by the U.S. FDA or other regulatory authorities. *** About TISSIUM TISSIUM, a privately-owned MedTech company based in Paris, France and Cambridge, USA, is dedicated to the development and commercialization of products derived from its unique proprietary family of fully biosynthetic, biomorphic, and programmable polymers platform. The company's products will address multiple unmet clinical needs, including atraumatic tissue repair and tissue reconstruction. Currently, the Company has a pipeline of seven products across three verticals, including atraumatic sutureless nerve repair, atraumatic hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products. TISSIUM's technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital), who co-founded the company in 2013. For more information, please visit: and follow us on LinkedIn: TISSIUM. *** Contact Romain Attard – Chief Financial Officer rattard@ in to access your portfolio
